Please use this identifier to cite or link to this item:
Title: Altered levels of blood proteins in Alzheimer's disease longitudinal study: results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort
Austin Authors: Gupta, Veer Bala;Hone, Eugene;Pedrini, Steve;Doecke, James;O'Bryant, Sid;James, Ian;Bush, Ashley I;Rowe, Christopher C ;Villemagne, Victor L ;Ames, David;Masters, Colin L ;Martins, Ralph N;AIBL Research Group
Affiliation: Austin Health, Heidelberg, Victoria, Australia
School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia
Co-operative Research Centre for Mental Health, Carlton, Victoria, Australia
CSIRO Health and Biosecurity/Australian E-Health Research Centre, Brisbane, Queensland, Australia
Institute for Healthy Aging, University of North Texas Health Science Center, Fort Worth, TX, USA
School of Engineering and Information Technology, Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia
The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia
Department of Molecular Imaging & Therapy and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
National Ageing Research Institute, Parkville, Victoria, Australia
Academic Unit for Psychiatry of Old age, St. George's Hospital, The University of Melbourne, Melbourne, Victoria, Australia
School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, Australia
Issue Date: 23-Apr-2017 2017-04-23
Publication information: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring 2017; 8: 60-72
Abstract: INTRODUCTION: A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. METHODS: We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. RESULTS: Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P = .0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P = .0008). DISCUSSION: These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.
DOI: 10.1016/j.dadm.2017.04.003
ORCID: 0000-0003-3910-2453
Journal: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
PubMed URL:
Type: Journal Article
Subjects: Alzheimer's disease
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 2, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.